HC Wainwright Has Positive Estimate for OKUR FY2025 Earnings

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – Equities research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of OnKure Therapeutics in a research note issued on Monday, November 10th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($4.53) per share for the year, up from their previous forecast of ($4.56). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q4 2025 earnings at ($1.12) EPS, Q1 2026 earnings at ($1.15) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.20) EPS, Q4 2026 earnings at ($1.23) EPS and FY2026 earnings at ($4.76) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.11.

A number of other equities analysts also recently commented on OKUR. Weiss Ratings reissued a “sell (e+)” rating on shares of OnKure Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of OnKure Therapeutics to a “sell” rating in a report on Saturday, November 1st. Finally, Zacks Research lowered shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, OnKure Therapeutics has an average rating of “Moderate Buy” and an average price target of $32.33.

OnKure Therapeutics Price Performance

OKUR opened at $3.08 on Wednesday. The business has a fifty day moving average price of $2.86 and a 200 day moving average price of $2.58. OnKure Therapeutics has a 12 month low of $1.70 and a 12 month high of $17.44. The stock has a market capitalization of $41.67 million, a price-to-earnings ratio of -0.64 and a beta of 0.46.

Institutional Trading of OnKure Therapeutics

Several institutional investors have recently modified their holdings of OKUR. ADAR1 Capital Management LLC purchased a new position in shares of OnKure Therapeutics in the 1st quarter valued at $43,000. XTX Topco Ltd purchased a new stake in OnKure Therapeutics in the second quarter valued at $25,000. Bailard Inc. acquired a new position in OnKure Therapeutics in the second quarter valued at $34,000. Rangeley Capital LLC purchased a new position in shares of OnKure Therapeutics during the second quarter worth about $71,000. Finally, GSA Capital Partners LLP grew its holdings in shares of OnKure Therapeutics by 172.1% during the third quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock worth $163,000 after purchasing an additional 37,459 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.